Gilead's Little Tweak Could Produce Big Revenue
Sometimes it's the little things companies do that can have the biggest impacts on their bottom line.
Take Gilead Sciences (NASDAQ: GILD), which is working on swapping out tenofovir disoproxil fumarate, which goes by the brand name Viread, for tenofovir alafenamide, commonly referred to as TAF, in its HIV drug cocktails. The chemical structures are similar -- thus sharing the base tenofovir name -- and the drugs acts in the same way to inhibit the replication of the virus, but one little change could have a huge impact on the biotech.
Hey, check out all the research scientist jobs. Post your resume today!
Take Gilead Sciences (NASDAQ: GILD), which is working on swapping out tenofovir disoproxil fumarate, which goes by the brand name Viread, for tenofovir alafenamide, commonly referred to as TAF, in its HIV drug cocktails. The chemical structures are similar -- thus sharing the base tenofovir name -- and the drugs acts in the same way to inhibit the replication of the virus, but one little change could have a huge impact on the biotech.
Hey, check out all the research scientist jobs. Post your resume today!